Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05578092 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
A Phase 1 study, sponsored by Mirati Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT05578092 is a Phase 1 study that was terminated before completion, run by Mirati Therapeutics. The registered enrollment target is 64 participants.
The verdict
NCT05578092, a Phase 1 study, was terminated before completion, sponsored by Mirati Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways.
Interventions
- DRUG MRTX849
- DRUG MRTX0902
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2022-12-02 |
| Est. Completion | 2026-02-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05578092
The ClinicalTrials.gov registry entry for NCT05578092 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MRTX849 is the first listed.
NCT05578092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05578092 about?
NCT05578092 is a clinical study titled "A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway". This is a Phase 1, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways.
What is the current status of trial NCT05578092?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2022-12-02. Estimated completion is 2026-02-03.
What interventions are being tested in trial NCT05578092?
The interventions under investigation include: MRTX849 (DRUG), MRTX0902 (DRUG).
Who is sponsoring clinical trial NCT05578092?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.